PAVELKA, Karel, Kateřina JAROŠOVÁ, David SUCHÝ, Ladislav ŠENOLD, Karel CHROUST, Ladislav DUŠEK and Jiří VENCOVSKÝ. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Annals of the Rheumatic Diseases. London: BMI Journals, 2009, vol. 68, No 8, 6 pp. ISSN 0003-4967.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy.
Name in Czech Zvýšení dávky Infliximabu u pacientů s revmatoidní artritidou: randomizovaná dvojitě zaslepená studie bez potvrzení účinnosti
Name (in English) Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy.
Authors PAVELKA, Karel, Kateřina JAROŠOVÁ, David SUCHÝ, Ladislav ŠENOLD, Karel CHROUST, Ladislav DUŠEK and Jiří VENCOVSKÝ.
Edition Annals of the Rheumatic Diseases, London, BMI Journals, 2009, 0003-4967.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 8.111
Organization unit Faculty of Medicine
UT WoS 000268010500009
Keywords (in Czech) revmatoidní artritida; terapie; infliximab; zvýšení dávky
Keywords in English rheumatoid arthritis; therapy; infliximab; dose escalation
Tags dose escalation, infliximab, rheumatoid arthritis, THERAPY
Changed by Changed by: prof. RNDr. Ladislav Dušek, Ph.D., učo 670. Changed: 4/3/2010 14:54.
Abstract
In this study, increasing the infliximab dose from 3 to 5 mg/kg in RA patients with residual disease activity did not improve efficacy but moderately increased toxicity. These data indicate that a switch to another biological treatment would be a more appropriate strategy in incomplete responders.
Abstract (in English)
In this study, increasing the infliximab dose from 3 to 5 mg/kg in RA patients with residual disease activity did not improve efficacy but moderately increased toxicity. These data indicate that a switch to another biological treatment would be a more appropriate strategy in incomplete responders.
PrintDisplayed: 24/5/2024 03:42